100% Quality Guarantee
PhD-Level Technical Support
Anti-CTLA4 ipilimumab biosimilar mAb HDBS0022
Key Features

ipilimumab Biosimilar (CTLA-4) Antibody (HDBS0022)

SKU HDBS0022
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Inflammatory Response Assays
Applications Pharmacokinetics
Disease Area Cancer Immunotherapy
Disease Area Autoimmune Diseases
Protein CTLA-4
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

ipilimumab Biosimilar (CTLA-4) Antibody (HDBS0022)

The Ipilimumab CTLA-4 Biosimilar Antibody is a highly specific antibody designed for research applications involving cytotoxic T-lymphocyte associated antigen 4 (CTLA-4), a key immune checkpoint protein that plays a critical role in regulating the immune response. This antibody, produced through biosimilar technology, offers researchers a reliable tool for studying the function of CTLA-4 in various biological systems.With its high affinity and specificity for CTLA-4, this biosimilar antibody enables accurate detection and analysis of CTLA-4 expression in human samples, making it ideal for use in techniques such as immunohistochemistry and flow cytometry.

By targeting CTLA-4, researchers can gain valuable insights into immune regulation mechanisms and develop innovative approaches for the treatment of cancer and autoimmune diseases.The Ipilimumab Anti-CTLA-4 Biosimilar Antibody holds great promise for advancing our understanding of immune checkpoint pathways and developing novel immunotherapies. Its superior performance and reliability make it a valuable asset for researchers in the fields of oncology, immunology, and drug development. Unlock the potential of CTLA-4 research with this cutting-edge biosimilar antibody.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose